You are here

Tecentriq Approved As First Immunotherapy for Breast Cancer

For Locally Advanced or Metastatic Triple-Negative Type Only

Roche’s cancer immunotherapy drug Tecentriq (atezolizumab), a PD-L1 inhibitor, has received its fifth FDA approval, for advanced triple-negative breast cancer. Before this decision, no immunotherapies had been approved for any form of breast cancer.

The approval is only for locally advanced or metastatic triple-negative breast cancer expressing PD-L1, the molecule that locks onto PD-1 receptors on the surface of T cells. The PD-L1/PD-1 “handshake” blocks T cells from attacking the tumor. The first drugs that were developed to prevent the handshake, such as Bristol-Myers Squibb’s nivolumab and Merck’s pembrolizumab, target PD-1. Tecentriq binds with PD-L1, preventing the T-cell-sidelining handshake.

Despite all of the attention that immunotherapies have received, they help only a minority of patients. Data on overall survival aren’t final, but at last report, the Tecentriq patients with PD-L1-positive tumors had a median overall survival of 25 months, compared to 15.5 months for chemo-only patients.

Although the FDA approval was based on progression-free survival and on the fact that patients with triple-negative breast cancer have essentially no options, continued approval for triple-negative breast cancer “may be contingent upon verification and description of clinical benefit in a confirmatory trial(s),” Genentech, the Roche division that developed Tecentriq, said in a statement.

The American Cancer Society projects that about 40,000 people in the U.S. will be diagnosed with triple-negative breast cancer in 2019.

Source: STAT, March 8, 2019

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
National Statistics Report Factors In Race, Ethnicity for the First Time